

Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

☒ Commercial (Small & Large Group)

 \boxtimes ASO

⊠ Exchange/ACA

⋈ Medicare Advantage (MAPD)

New-to-Market Medical Pharmacy Products Currently Under Clinical Review MB2210

Covered Service: Yes

Prior Authorization

Required: N/A

Additional

Information: None

Medicare Policy: Prior authorization is not required for Medicare Cost products

(Dean Care Gold) and Medicare Supplement (Select) when this drug is provided by participating providers. Prior authorization is required if a member has Medicare primary and the plan

secondary coverage. This policy is not applicable to our

Medicare Replacement products.

Wisconsin Medicaid Policy

Coverage of prescription drug benefits is administered by the Wisconsin Medicaid program. Coverage of medical drug benefits

is administered by the Wisconsin Medicaid fee-for-service

program. Medical drugs not paid on a fee-for-service basis by the Wisconsin Medicaid program are covered by the plan with no PA

required.



Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

Updated 06/18/2025

Brand name	Generic name	J code	National Drug	Date of FDA
Diana name	Cenerio name	o code	Codes (NDCs)	approval
Bomyntra	denosumab-bnht	J3590	65219-0670-01	March 25, 2025
			65219-0672-01	
Conexxence	denosumab-bnht	J3590	65219-0668-01	March 25, 2025
denosumab-bnht	denosumab-bnht	J3590	Multiple	March 25, 2025
denosumab-dssb	denosumab-dssb	J3590	71202-0013-10	February 13, 2025
eculizumab-aagh	eculizumab-aagh	Q5151	n/a	April 30, 2025
Emrelis	telisotuzumab vedotin-tllv	J9999	00074-1044-01	May 14, 2025
			00074-1055-01	
Ibtrozi	taletrectinib	J8999	84651-0200-30	June 11, 2025
Imaavy	nipocalimab-aahu	J3590	57894-0800-01	April 29, 2025
-			57894-0801-01	
Jobevne	bevacizumab-nwgd	J9999	83257-0009-11	April 9, 2025
			83257-0010-11	
omalizumab-igec	omalizumab-igec	J3590	72606-0052-01	March 7, 2025
	-		72606-0053-01	
Omlyclo	omalizumab-igec	J3590	72606-0035-01	March 7, 2025
			72606-0036-01	
Osenvelt	denosumab-bmwo	J3590	72606-0038-01	February 28, 2025
Ospomyv	denosumab-dssb	J3590	71202-0012-10	February 13, 2025
pegfilgrastim-fpgk	pegfilgrastim-fpgk	J3590	TBD	March 26, 2025
Starjemza	ustekinumab-hmny	J3590	00143-9171-01	May 22, 2025
Stoboclo	denosumab-bmwo	J3590	72606-0037-01	February 28, 2025
tocilizumab-aazg	tocilizumab-aazg	Q5135	Multiple	May 12, 2025
trastuzumab-pkrb	trastuzumab-pkrb	Q5113	51759-0225-13	May 22, 2025
			51759-0226-26	
ustekinumab	ustekinumab	J3358	Multiple	April 1, 2025
ustekinumab-aauz	ustekinumab-aauz	Q9999	Multiple	April 14, 2025
ustekinumab-stba	ustekinumab-stba	Q5099	Multiple	April 28, 2025
Xbryk	denosumab-dssb	J3590	71202-0014-01	February 13, 2025
Zevaskyn	prademagene zamikeracel	J3590	84103-0007-01	April 29, 2025
Zusduri	mitomycin	J9999	72493-0106-03	June 12, 2025

Note: Drugs recently removed from this list have been addressed under new drug management policies.

This list is provided for our provider network's convenience and information. While this list is intended to be comprehensive, the U.S. Food and Drug Administration (FDA) approval process and its timing is outside of the Plan's control. The Plan reserves the right to adjust claims for any new-to-market medical pharmacy products as discussed in the 'New-to-Market Medical Pharmacy Products' coverage policy.



Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

	Committee/Source	Date(s)
Document Created:	Medical Policy Committee/Health Services Division/Pharmacy Services	July 20, 2022
Revised:	Medical Policy Committee/Health Services Division/Pharmacy Services Medical Policy Committee/Health Services Medical Policy Committee/Health Services	September 21, 2022
		February 15, 2023
		April 19, 2023
		May 17, 2023
		June 21, 2023
	Division/Pharmacy Services Medical Policy Committee/Health Services Division/Pharmacy Services	July 19, 2023
	Medical Policy Committee/Health Services Division/Pharmacy Services	August 16, 2023 September 20, 2023
	Medical Policy Committee/Health Services Division/Pharmacy Services	October 18, 2023
	Medical Policy Committee/Health Services Division/Pharmacy Services	November 15, 2023
	Medical Policy Committee/Health Services Division/Pharmacy Services Medical Policy Committee/Health Services	December 20, 2023
	Division/Pharmacy Services Medical Policy Committee/Health Services	February 21, 2024
	Division/Pharmacy Services Medical Policy Committee/Health Services	March 20, 2024
	Division/Pharmacy Services Medical Policy Committee/Health Services	April 17, 2024
	Division/Pharmacy Services Medical Policy Committee/Health Services Division/Pharmacy Services	May 15, 2024 June 20, 2024
	Medical Policy Committee/Health Services Division/Pharmacy Services Medical Policy Committee/Health Services Division/Pharmacy Services Medical Policy Committee/Health Services Division/Pharmacy Services	July 17, 2024
		August 21, 2024
		September 11, 2024



Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

	Committee/Source	Date(s)		
	Medical Policy Committee/Health Services Division/Pharmacy Services	November 21, 2024,		
		December 19, 2024,		
		January 16, 2025,		
		March 20, 2025,		
		April 17, 2025;		
		May 15, 2025		
		June 18, 2025		
Reviewed:	Medical Policy Committee/Health Services Division/Pharmacy Services	September 21, 2022		
	Medical Policy Committee/Health Services Division/Pharmacy Services	February 15, 2023		
	Medical Policy Committee/Health Services Division/Pharmacy Services Medical Policy Committee/Health Services	April 19, 2023		
	Division/Pharmacy Services Medical Policy Committee/Health Services	May 17, 2023		
	Division/Pharmacy Services Medical Policy Committee/Health Services	June 21, 2023		
	Division/Pharmacy Services Medical Policy Committee/Health Services	July 19, 2023		
	Division/Pharmacy Services Medical Policy Committee/Health Services	August 16, 2023		
	Division/Pharmacy Services Medical Policy Committee/Health Services	September 20, 2023		
	Division/Pharmacy Services Medical Policy Committee/Health Services	October 18, 2023		
	Division/Pharmacy Services Medical Policy Committee/Health Services Division/Pharmacy Services	November 15, 2023		
	Division/Pharmacy Services Medical Policy Committee/Health Services Division/Pharmacy Services	December 20, 2023 February 21, 2024		
	Medical Policy Committee/Health Services Division/Pharmacy Services	March 20, 2024		
New-to-Market Medical Pharmacy				



Coverage of any drug intervention discussed in a Medica prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and applicable state and/or federal laws.

Committee/Source	Date(s)	
Medical Policy Committee/Health Services		
Division/Pharmacy Services Medical Policy Committee/Health Services	April 17, 2024	
Division/Pharmacy Services	May 15, 2024	
Medical Policy Committee/Health Services Division/Pharmacy Services	June 20, 2024	
Medical Policy Committee/Health Services		
Division/Pharmacy Services Medical Policy Committee/Health Services	July 17, 202	
Division/Pharmacy Services	August 21, 2024	
Medical Policy Committee/Health Services Division/Pharmacy Services	September 11, 2024	
Medical Policy Committee/Health Services	November 21, 2024	
Division/Pharmacy Services Medical Policy Committee/Health Services	November 21, 2024,	
Division/Pharmacy Services Medical Policy Committee/Health Services	December 19, 2024,	
Division/Pharmacy Services	January 16, 2025,	
Medical Policy Committee/Health Services Division/Pharmacy Services	March 20, 2025,	
Medical Policy Committee/Health Services		
Division/Pharmacy Services Medical Policy Committee/Health Services	April 17, 2025;	
Division/Pharmacy Services	May 15, 2025;	
Medical Policy Committee/Health Services Division/Pharmacy Services	June 18, 2025	
Medical Policy Committee/Health Services Division/Pharmacy Services		
Division, i namiday ou vioco		

Effective: 06/18/2025 Published: 06/18/2025